The proteostasis boundary in misfolding diseases of membrane traffic
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Protein function is regulated by the proteostasis network (PN) [Balch, W.E., Morimoto, R.I., Dillin, A. and Kelly, J.W. (2008) Adapting proteostasis for disease intervention. Science 319, 916–919], an integrated biological system that generates and protects the protein fold. The composition of the PN is regulated by signaling pathways including the unfolded protein response (UPR), the heat‐shock response (HSR), the ubiquitin proteasome system (UPS) and epigenetic programs. Mismanagement of protein folding and function during membrane trafficking through the exocytic and endocytic pathways of eukaryotic cells by the PN is responsible for a wide range of diseases that include, among others, lysosomal storage diseases, myelination diseases, cystic fibrosis, systemic amyloidoses such as light chain myeloma, and neurodegenerative diseases including Alzheimer's. Toxicity from misfolding can be cell autonomous (affect the producing cell) or cell non‐autonomous (affect a non‐producing cell) or both, and have either a loss‐of‐function or gain‐of‐toxic function phenotype. Herein, we review the role of the PN and its regulatory transcriptional circuitry likely to be operational in managing the protein fold and function during membrane trafficking. We emphasize the enabling principle of a ‘proteostasis boundary (PB)’ [Powers, E.T., Morimoto, R.T., Dillin, A., Kelly, J.W., and Balch, W.E. (2009) Biochemical and chemical approaches to diseases of proteostasis deficiency. Annu. Rev. Biochem. 78, 959–991]. The PB is defined by the combined effects of the kinetics and thermodynamics of folding and the kinetics of misfolding, which are linked to the variable and adjustable PN capacity found different cell types. Differences in the PN account for the versatility of protein folding and function in health, and the cellular and tissue response to mutation and environmental challenges in disease. We discuss how manipulation of the folding energetics or the PB through metabolites and pharmacological intervention provides multiple routes for restoration of biological function in trafficking disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms linking obesity to insulin resistance and type 2 diabetes
Kahn, S. E., Hull, R. L., & Utzschneider, K. M. (2006) · Nature · doi:10.1038/nature05482 · Cited by 5,448 · cited 1×
“As final example, it is not necessary have to a folding defect to challenge the PN, as even excessive expression of wild-type proteins in response to the metabolome defined by diet can trigger disease as evident in type II diabetes [11,65–67].”
BackgroundInflammation, stress, and diabetes
Wellen, K. E., & Hotamisligil, G. S. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25102 · Cited by 4,143
Goh, K.-I., Cusick, M. E., Valle, D., Childs, B., Vidal, M., & Barabási, A.-L. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701361104 · Cited by 3,242
Adapting Proteostasis for Disease Intervention
Balch, W. E., Morimoto, R. I., Dillin, A., & Kelly, J. W. (2008) · Science · doi:10.1126/science.1141448 · Cited by 2,495 · cited 5×
“Alternatively, correction could be achieved using proteostasis regulators [1], molecules that adjust the composition and/or concentration of the PN and hence the PB.”
BackgroundInfluentialSelf-citationSmall molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes
Milne, J. C., Lambert, P. D., Schenk, S., Carney, D. P., Smith, J. J., Gagne, D. J., Jin, L., Boss, O., Perni, R. B., Vu, C. B., et al. (2007) · Nature · doi:10.1038/nature06261 · Cited by 1,707 · cited 1×
“Strikingly, global modulators of the FRS, including the histone deacetylase inhibitors (HDACi) including 4-PBA [72,73] and activators of sirtuins [74–77] were found to attenuate the FRS response and restore β-cell homeostasis.”
BackgroundThe Role for Endoplasmic Reticulum Stress in Diabetes Mellitus
Eizirik, D. L., Cardozo, A. K., & Cnop, M. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0015 · Cited by 1,173
Dill, K. A., Ozkan, S. B., Shell, M. S., & Weikl, T. R. (2008) · Annual Review of Biophysics · doi:10.1146/annurev.biophys.37.092707.153558 · Cited by 1,163
Biological and Chemical Approaches to Diseases of Proteostasis Deficiency
Powers, E. T., Morimoto, R. I., Dillin, A., Kelly, J. W., & Balch, W. E. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.052308.114844 · Cited by 1,149
Self-citationProteotoxic stress and inducible chaperone networks in neurodegenerative disease and aging
Morimoto, R. I. (2008) · Genes & Development · doi:10.1101/gad.1657108 · Cited by 872
Ideker, T., & Sharan, R. (2008) · Genome Research · doi:10.1101/gr.071852.107 · Cited by 817
Gut hormones and the regulation of energy homeostasis
Murphy, K. G., & Bloom, S. R. (2006) · Nature · doi:10.1038/nature05484 · Cited by 778 · cited 1×
“The PN is controlled both cell autonomously and cell non-autonomously, the latter involving both neuronal and non-neuronal signaling pathways [23,24].”
BackgroundProgressive disruption of cellular protein folding in models of polyglutamine diseases
Gidalevitz, T., Ben-Zvi, A., Ho, K. H., Brignull, H. R., & Morimoto, R. I. (2006) · Science · doi:10.1126/science.1124514 · Cited by 643 · cited 1×
“Instead, the capacity of the PN may be adjusted to provide just enough capacity for the folding load in a given cell type at a given time [5,29,30].”
BackgroundCFTR Function and Prospects for Therapy
Riordan, J. R. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.103004.142532 · Cited by 610 · cited 8×
“The most common mutation in CF disease is the Phe508 deletion (DF508 CFTR).”
BackgroundInfluentialGregor, M. F., & Hotamisligil, G. S. (2007) · Journal of Lipid Research · doi:10.1194/jlr.r700007-jlr200 · Cited by 586 · cited 1×
“Here, a high-fat diet, a lack of exercise, and genetic factors strongly impact the ability of the PN to maintain the function of β-cells in the pancreas in response to excessive insulin demand [4,68,69].”
BackgroundAutophagy: Basic Principles and Relevance to Disease
Kundu, M., & Thompson, C. B. (2008) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathmechdis.2.010506.091842 · Cited by 523 · cited 1×
“These not only alter the inherited capacity of the proteostasis program, but are sensed by the FRS and the DRS, which can either resolve the problem or promote cell death in the case of severe pathology [19–22].”
BackgroundThe Hsp90 molecular chaperone: an open and shut case for treatment
Pearl, L. H., Prodromou, C., & Workman, P. (2008) · Biochemical Journal · doi:10.1042/bj20071640 · Cited by 447
Genetic diseases of connective tissues: cellular and extracellular effects of ECM mutations
Bateman, J. F., Boot-Handford, R. P., & Lamandé, S. R. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2520 · Cited by 338 · cited 1×
“Examples of CAT include mutations in diseases of myelinating cells (including Charcot-Marie-Tooth disease, Pelizaeus-Merzbacher disease and Multiple Sclerosis) [50], diseases of connective tissues (ECM) [51], diseases of the eye including retinitis pigmentosa [52], mutations in the LDL-receptor that results in ER accu…”
BackgroundAn Adaptable Standard for Protein Export from the Endoplasmic Reticulum
Wiseman, R. L., Powers, E. T., Buxbaum, J. N., Kelly, J. W., & Balch, W. E. (2007) · Cell · doi:10.1016/j.cell.2007.10.025 · Cited by 155 · cited 7×
“Like FoldEx, the FRS and DRS that regulate the composition and levels of proteostasis components are accommodated in the model by the adjustable concentrations of the PN components [17,28].”
BackgroundMethodInfluentialSelf-citation
Cited by
Basic mechanisms of neurodegeneration: a critical update
Jellinger, K. A. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2010.01010.x · Cited by 596
The Unfolded Protein Response: Integrating Stress Signals Through the Stress Sensor IRE1α
Hetz, C., Martinon, F., Rodriguez, D., & Glimcher, L. H. (2011) · Physiological Reviews · doi:10.1152/physrev.00001.2011 · Cited by 569
Protein Homeostasis and Aging: the importance of exquisite quality control
Koga, H., Kaushik, S., & Cuervo, A. M. (2011) · Ageing research reviews · doi:10.1016/j.arr.2010.02.001 · Cited by 476
Protein Folding and Quality Control in the ER
Araki, K., & Nagata, K. (2011) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a007526 · Cited by 413
Villella, V. R., Esposito, S., Bruscia, E. M., Maiuri, M. C., Raia, V., Kroemer, G., & Maiuri, L. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00001 · Cited by 389
Metadata
- Authors
- Hutt, D. M., Powers, E. T., & Balch, W. E.
- Venue
- FEBS Letters
- Publisher
- Wiley
- Published
- 2009-07-12
- Volume
- 583
- Issue
- 16
- Pages
- 2639-2646
- ISSN
- 0014-5793 (ISSN-L)
- 1873-3468
- OpenAlex
- W2169409747
- Cited by
- 84
- References
- 18
- FWCI
- 3.84
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.